TMEM158 and prostate cancer: In a cohort of early-onset prostate cancer patients (20), TMEM158 expression levels were shown at a significantly lower level in late-stage tumors (Figure 3B), higher Gleason scores tumors (Figure 3C), and biochemically relapsed (BCR) cancers (Figure 3D).